Engineered antibody for inhibition of fibrosis
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 3, 2017
Issued Date -
N/A
app pub date -
Feb 26, 2013
filing date -
Apr 20, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO: 1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the α2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 2 Citation Count
- A61K Class
- 45.09 % this patent is cited more than
- 8 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 3, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 3, 2029 |
